Hints and tips:
Related Special Reports
...David Moore, vice-president for corporate development, added that the company would focus on acquisitions in diabetes and obesity, ideally in the early stage of development....
...The Development Bank of Japan is investing in 4Bio, which funds companies in the UK and Europe, alongside the Japanese pharma group Kyowa Kirin, and US healthcare provider, Children’s Minnesota. 4Bio aims...
...It has also worked on drug development for US pharma company Johnson & Johnson, Danish biotech group Genmab and British biotech Iksuda therapeutics....
...The company, which provided lixisenatide free of charge to the French research but did not sponsor it, welcomed the results....
...It has pledged to double funding for dementia research to £160mn a year by 2025....
...US federal prosecutors are also probing an Adani company and the group’s founder for potential bribery violations....
...Susan Galbraith, executive vice-president of oncology research and development at AstraZeneca, said there was an “opportunity to improve” on existing drugs in the area and that the Fusion acquisition would...
...Martin Holst Lange, head of development at Novo Nordisk, said that Cardior’s drug had the “potential to become a first-in-class therapy designed to halt or partially reverse the course of disease for people...
...Dr Matthew Hobbs, director of research at Prostate Cancer UK, said such changes had “made the process safer and more accurate” but better evidence was needed to understand their full impact....
...At the end of 2020 Volkswagen opened a research and development centre in Anhui province, and owns a major stake in Guoxuan, a Chinese battery firm....
...A dearth of career scientists and public funding risks undermining efforts to use technological breakthroughs to tackle the biggest health threats, the head of a leading international research organisation...
...The company has found that the technology can reduce both the time and cost of the pre-clinical testing phase of drug development by 45 per cent, Asif Hasan, co-founder of Quantiphi told me....
...The company would present more precise survival data from the Tagrisso trial at a conference later this year, she added....
...This would result in FDA action being delayed beyond the first quarter, the company said in its statement....
...Citadel, which manages roughly $61bn, made a record $16bn in profit for investors in 2022, according to research from LCH Investments....
...Jodie Keane Senior Research Fellow ODI (Formerly Overseas Development Institute), London SE1, UK...
...About 1,000 people in England would have been eligible for the treatment, according to estimates by the watchdog and companies....
...He sold off assets in non-core areas to invest heavily in research and development, plus fund acquisitions. There were setbacks, including criticism over its accounting practices....
...In 2022/23, NIHR research expenditure for all cancers was £121.8mn.”...
...other drug development....
...According to health data company Airfinity, there are 232 anti-obesity medications at various stages of development, from pre-clinical studies on animals to late-stage, phase 3 trials....
...In the past year, Novo Nordisk has become Europe’s largest company by market capitalisation, while Eli Lilly overtook Johnson & Johnson as the world’s most valuable pharma company, on the back of high demand...
...For that reason, the 2023 FT Person of the Year went to Lars Fruergaard Jørgensen, chief executive of Novo Nordisk, the pharmaceutical company that brought these successful weight-loss drugs to market....
...“The top-level decision many companies are making is: should we use an LLM and which should we use?” said Rishi Bommasani, who leads a team at the Stanford Center for Research on Foundation Models....
...“But the elegant synthetic design of cresomycin, based on an intuitive rationale, provides an exciting scaffold for further development.”...
International Edition